Managing Director

Dean Slagel

Dean Slagel is a British national with 23 years of biopharmaceutical industry and venture investing experience and an MBA from ENPC Business School, Paris. Following a 4 year global marketing management role at Tillotts Pharma, he spent 10 years with Ferring in global operations and global business development management. He has led Esperante since 2004, building an investment portfolio of up to 21 companies across North America and Europe. During this period, Esperante completed two successful exits (Thiakis and Pinnacle Biologics) and an IPO (Cara). Mr Slagel is currently a Board Director of Altacor, Arquer Diagnostics, Atox Bio, Cara Therapeutics, Canbex and Haemostatix.

+44 (0)7796 017 725 |


Erik Schropp

Erik Schropp is currently Group Financial Officer of the C&P Group and previously International Tax Manager and Finance Director of the Ferring Group, International Tax Manager of Unisource NV and Tax Manager at Arthur Andersen (Netherlands).

Advisor (Consultant)

Sandy Primrose PhD MBE

Dr Primrose is a non-executive director and Chairman of Urosens, Fios Genomics, Arrayjet and Cellexus. Dr Primrose is also the senior partner at Business and Technology Management, a biotechnology and healthcare consultancy. Dr Primrose was previously an academic at Warwick University and subsequently was Senior Director of Drug Development at Searle Research and Development and then managed the life science business of Amersham International (now part of GE). He has also since held senior management positions in a number of early stage companies as well as serving on the board of the Microbiological Research Authority and thereafter the Health Protection Agency.